<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increased action potential duration (APD) induces early afterdepolarization (EAD) in vitro and <z:hpo ids='HP_0001664'>torsade de pointes</z:hpo> in vivo, and ATP-sensitive <z:chebi fb="0" ids="29103">K(+)</z:chebi> channel openers decrease APD in cardiac tissue </plain></SENT>
<SENT sid="1" pm="."><plain>We tested whether the ATP-sensitive <z:chebi fb="0" ids="29103">K(+)</z:chebi> channel opener nicorandil has antiarrhythmic effects on class III antiarrhythmic drug-induced <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In 10 anesthetized dogs with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001678'>atrioventricular block</z:hpo>, we recorded monophasic action potentials (MAPs) from the left and right ventricular (LV and RV) endocardium </plain></SENT>
<SENT sid="3" pm="."><plain>The class III antiarrhythmic drug nifekalant (1 mg/kg, IV) was administered at 5 minute intervals (total doses; 2-6 mg/kg) until the appearance of EADs, <z:hpo ids='HP_0006682'>premature ventricular contractions</z:hpo> (<z:mp ids='MP_0010018'>PVCs</z:mp>), or polymorphic <z:hpo ids='HP_0004756'>ventricular tachycardias</z:hpo> (PVTs) </plain></SENT>
<SENT sid="4" pm="."><plain>Five minutes after the end of nifekalant administration, nicorandil (1.0 mg/kg) was administered over 5 minutes </plain></SENT>
<SENT sid="5" pm="."><plain>Nifekalant decreased the ventricular escape rate from 75 ± 5 beats/minute to 45 ± 10 beats/minute and increased RV-MAP duration (MAPD) from 217 ± 32 msec to 308 ± 2 msec (P &lt; 0.01) and LV-MAPD from 232 ± 32 msec to 353 ± 82 msec (P &lt; 0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>EADs were recorded in 9 dogs, frequent <z:hpo ids='HP_0006682'>premature ventricular contractions</z:hpo> (<z:mp ids='MP_0010018'>PVCs</z:mp>) developed in 10 dogs, incessant PVTs developed in 3 dogs, and monomorphic <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> developed in 3 dogs after nifekalant administration </plain></SENT>
<SENT sid="7" pm="."><plain>Nicorandil decreased RV-MAPD to 267 ± 57 msec and LV-MAPD to 279 ± 44 msec </plain></SENT>
<SENT sid="8" pm="."><plain>It suppressed EADs, decreased the incidence of <z:mp ids='MP_0010018'>PVCs</z:mp>, and abolished PVT </plain></SENT>
<SENT sid="9" pm="."><plain>Nicorandil may be clinically useful for treatment of <z:mp ids='MP_0010018'>PVCs</z:mp> and PVTs accompanying acquired <z:hpo ids='HP_0001657'>long QT syndrome</z:hpo> </plain></SENT>
</text></document>